gynecology and obstetrics
Preeclampsia and Eclampsia
Prevention
 therapy in women with certain risk factors reduces the rate of severe preeclampsia and fetal growth restriction ( Prevention references , (81 mg/day) is recommended for patients with high-risk factors for preeclampsia (previous pregnancy with preeclampsia, multifetal gestation, renal disorders, autoimmune disorders, type 1 or type 2 diabetes mellitus, chronic hypertension). It is also recommended for those with > 1 moderate-risk factors (first pregnancy, maternal age ≥ 35, body mass index > 30, family history of preeclampsia, sociodemographic characteristics such as African American race or low socioeconomic status, personal history factors such as low-birth-weight or small-for-gestational-age infants, previous adverse pregnancy outcome, or a> 10-year pregnancy interval [ Prevention references ]). Aspirinprophylaxis should be started at 12 to 28 weeks of gestation (ideally before 16 weeks) and continued until delivery. 1.Roberge S, Nicolaides K, Demers S et al: The role ofaspirindose on the prevention of preeclampsia and fetal growth restriction: Systematic review and meta-analysis.Am J Obstet Gynecol216 (2):110–120.e6, 2017. doi: 10.1016/j.ajog.2016.09.076 2.Meher S, Duley L, Hunter K, Askie L: Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: An individual participant data meta-analysis.Am J Obstet Gynecol216 (2):121–128.e2, 2017. doi: 10.1016/j.ajog.2016.10.016 3.American College of Obstetricians and Gynecologists (ACOG): Gestational hypertension and preeclampsia: ACOG Practice Bulletin, Number 222.Obstet Gynecol135 (6):e237–e260, 2020. 